0
Hansa Biopharma appoints new Chief Executive Officer
https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-appoints-new-chief-executive-officer/
Lund, Sweden, 24 April 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Søren Tulstrup will be stepping down from his position by mutual agreement as CEO after seven years of dedicated service to the Company.
https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-appoints-new-chief-executive-officer/
Lund, Sweden, 24 April 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Søren Tulstrup will be stepping down from his position by mutual agreement as CEO after seven years of dedicated service to the Company.
24/4 2025 07:08 exitnu 0126035 En super nyhed - a match in heaven, Aguiar-Lucander gjorde det virkeligt godt da hun var CEO i Calliditas Therapeutics som blev solgt til Asahi Kasei Corporation.
"Aguiar-Lucander served for seven years as CEO of Calliditas Therapeutics AB where she successfully led the company through a dual listing on NASDAQ in both Sweden and the U.S. During her tenure, the company successfully launched and commercialized the first ever approved drug for immunoglobulin A (IgA) nephropathy in the U.S. and until it was acquired by Asahi Kasei Corporation of Japan in September 2024. Prior to that, Aguiar-Lucander had a long and successful career in the healthcare investment sector, holding senior roles in funds such as Omega Funds and 3i Group."
"Aguiar-Lucander served for seven years as CEO of Calliditas Therapeutics AB where she successfully led the company through a dual listing on NASDAQ in both Sweden and the U.S. During her tenure, the company successfully launched and commercialized the first ever approved drug for immunoglobulin A (IgA) nephropathy in the U.S. and until it was acquired by Asahi Kasei Corporation of Japan in September 2024. Prior to that, Aguiar-Lucander had a long and successful career in the healthcare investment sector, holding senior roles in funds such as Omega Funds and 3i Group."
24/4 2025 07:14 exitnu 0126036 Hermed også en stor tak til Søren Tulstrup for et stærkt lederskab og visionær indsats.
24/4 2025 07:36 LP90 0126037 det har jeg bedt om skulle ske de sidste par år så super der sker noget på den post lad os så få gang i salget og styr på de løbske omk. og få lukket aftaler noget hurtigere end det skete med Søren så ja tak til søren for at gå
24/4 2025 07:43 exitnu 0126038 En rettet emission vil måske være det helt rigtige i situationen, Renée kan måske trække i nogle tråde i sit netværk?
